Medicus Sciences Acquisition Corp.
MSACW
NASDAQ Capital Market0.00
USD
- -
- -
CIK
0001836517
ISIN
KYG5960S1241
CUSIP
G5960S124
Return %
Stock
S&P500
1Y
-99.32
26.53
3Y
-99.83
76.60
5Y
-99.83
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jacob Jay Gottlieb
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 152 West 57th Street New York City NY United States of America
- IPO Date
- Apr 5, 2021
- CIK
- 0001836517
- Similar Companies
- Business
- Medicus Sciences Acquisition Corp. (MSACW) operates as a blank check company focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily in the healthcare industry and particularly the medical technology sector. The company, incorporated in 2020 as a Cayman Islands exempted company and headquartered at 152 West 57th Street, Floor 20, New York, New York, conducted an initial public offering in February 2021 raising approximately $92 million in proceeds held in trust. It does not engage in significant operations or generate revenues prior to completing an initial business combination; its sponsor is Medicus Sciences Holdings LLC, affiliated with healthcare-focused investment funds Altium Capital Management, LP and Sio Capital Management, LLC. Key management includes CEO Michael Castor, M.D., Executive Chairman Jacob Gottlieb, M.D., CFO Judah Drillick, and CBO Eric Cheng. The company targeted opportunities in medical technology both in the United States and internationally but failed to consummate a business combination within its required timeframe. In February 2023, Medicus Sciences Acquisition Corp. announced its dissolution and liquidation after being unable to complete an initial business combination by the deadline specified in its amended charter; public shares were redeemed at approximately $10.18 per share, with trading of shares and warrants suspended effective February 21, 2023. Warrants (MSACW), originally exercisable post-combination and set to expire December 2, 2026, ceased trading and hold no value following the liquidation. No subsidiaries, parent relationships, partnerships, funding rounds, acquisitions, or new product launches occurred prior to liquidation.